Sakar Healthcare is trading at ₹1067.80, up +5.32%, following 14 oncology-product approvals across the EU, UK, and Canada announced September 1.
- Approvals included site variations for five additional products under a technology-transfer pact with Accord Healthcare.
- The rally extends a weekly gain of 15.78%, from ₹875.70 to ₹1,013.90 between August 31 and September 4.
- The latest increase appears linked to continued investor response to the regulatory expansion and strong momentum.